Recombinant factor VIIa use in cardiac surgery--expanding the arsenal therapy for intractable bleeding?
作者信息
Kogan A, Berman M, Stein M, Vidne B A, Raanani E
机构信息
Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petach Tikva, 49100 Israel.
出版信息
J Cardiovasc Surg (Torino). 2004 Dec;45(6):569-71.
PMID:15746637
Abstract
A 72-year-old patient was admitted for mitral valve replacement because of infective endocarditis. Severe intractable bleeding in the early postoperative period was successfully treated with recombinant activated factor VII (rFVIIa). Thereafter, recovery was uneventful, and the patient was discharged on postoperative day 16. The current clinical aspects and experience of rFVIIa use in cardiac surgery are discussed.
摘要
Zotero 插件